Evocutis plc is a leading dermatology company uniquely able to combine contract research for laboratory testing, advanced living skin models and clinical testing to offer a complete service for the development of skin care products and their ingredients.
Our aim is to advance the discovery of products through scientific development and validation within the cosmetic, personal care, pharmaceutical and medical device sectors and to provide our living skin equivalent model, LabSkinTM, to skin researchers, supported by our consultancy service.
We have ambitious growth targets. Our strategy for achieving long-term growth is: Building on our established reputation in skin expertise by further development of our advanced, specialist laboratory and clinical evaluations of skin care products for the health and cosmetic markets and out-licensing internally-developed technologies.
Founded: 2003 as a spin-out of the world-renowned Skin Centre at the University of Leeds.
Country of Incorporation and Operation: United Kingdom.
Admission to AIM: 2006 as Syntopix Group plc (SYN). From 20 October 2011, as Evocutis plc (EVO).
Directors: Tom Bannatyne (Non-executive Chairman), Dr Gwyn Humphreys (Interim CEO), Dr Richard A Bojar (CSO), Darren Bamforth (Finance Director) and Mike Townend (Non-executive Director).